Sanofi and Regeneron’s Dupixent last week became the first drug approved to treat eosinophilic esophagitis (EoE), a rare, progressive disease that causes severe inflammation of the esophagus. The FDA’s decision came more than two months before Dupixent’s original priority review date. The interleukin inhibitor was first approved in 2017, as a treatment for atopic dermatitis. For the treatment of atopic dermatitis, Dupixent holds covered or better status for 89% of all insured lives under the pharmacy benefit. 39% of insured lives have preferred access to Dupixent, largely with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 5/23/22